Clinical Trial Update: A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

A phase 2 study comparing CNTO 328 (siltuximab) plus Velcade-Melphalan-Prednisone (VMP) to VMP alone in previously untreated multiple myeloma. The results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CNTO 328
• Melphalan (Melphalan)
• PREDNISONE (Prednisone)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-18